title: Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
abstract: Tissue type transglutaminase (TG2) is a unique multifunctional protein that plays a role in many steps in the cancer metastatic cascade. Here, we examined the clinical (n = 93 epithelial ovarian cancers) and biological (in vitro adhesion, invasion, and survival and in vivo therapeutic targeting) significance of TG2 in ovarian cancer. The overexpression of TG2 was associated with significantly worse overall patient survival in both univariate and multivariate analyses. Transfection of TG2 into SKOV3ip1 cells promoted attachment and spreading on fibronectin-coated surfaces and increased the in vitro invasive potential of these cells. Conversely, TG2 silencing with small interfering RNA (siRNA) of HeyA8 cells significantly decreased the invasive potential of the cells and also increased docetaxel-induced cell death. In vivo therapy experiments using chemotherapy-sensitive (HeyA8) and chemotherapy-resistant (HeyA8-MDR and RMG2) models showed significant antitumor activity both with TG2 siRNA-1,2-dioleoyl-sn-glycero-3-phosphatidylcholine alone and in combination with docetaxel chemotherapy. This antitumor activity was related to decreased proliferation and angiogenesis and increased tumor cell apoptosis in vivo. Taken together, these findings indicate that TG2 overexpression is an adverse prognostic factor in ovarian carcinoma and TG2 targeting may be an attractive therapeutic approach.
authors.affiliation: Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Jee Young
authors.initials: JY
authors.lastname: Hwang
authors.forename: Lingegowda S
authors.initials: LS
authors.lastname: Mangala
authors.forename: Jansina Y
authors.initials: JY
authors.lastname: Fok
authors.forename: Yvonne G
authors.initials: YG
authors.lastname: Lin
authors.forename: William M
authors.initials: WM
authors.lastname: Merritt
authors.forename: Whitney A
authors.initials: WA
authors.lastname: Spannuth
authors.forename: Alpa M
authors.initials: AM
authors.lastname: Nick
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Fiterman
authors.forename: Pablo E
authors.initials: PE
authors.lastname: Vivas-Mejia
authors.forename: Michael T
authors.initials: MT
authors.lastname: Deavers
authors.forename: Robert L
authors.initials: RL
authors.lastname: Coleman
authors.forename: Gabriel
authors.initials: G
authors.lastname: Lopez-Berestein
authors.forename: Kapil
authors.initials: K
authors.lastname: Mehta
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002277:Carcinoma / Q000201:enzymology* / Q000378:metabolism; D045744:Cell Line, Tumor; D018450:Disease Progression; D005260:Female; D019204:GTP-Binding Proteins; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D020868:Gene Silencing; D006801:Humans; D051379:Mice; D009154:Mutation; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000378:metabolism; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases / Q000096:biosynthesis*
chemical_list: D000970:Antineoplastic Agents; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins